Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Oxaliplatin"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 486
Tytuł:
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Autorzy:
Ohkawa, S
Okusaka, T
Isayama, H
Fukutomi, A
Yamaguchi, K
Ikeda, M
Funakoshi, A
Nagase, M
Hamamoto, Y
Nakamori, S
Tsuchiya, Y
Baba, H
Ishii, H
Omuro, Y
Sho, M
Matsumoto, S
Yamada, N
Yanagimoto, H
Unno, M
Ichikawa, Y
Pokaż więcej
Źródło:
British Journal of Cancer. 4/28/2015, Vol. 112 Issue 9, p1428-1434. 7p. 1 Diagram, 4 Charts, 2 Graphs.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.
Autorzy:
Carrasco J; Department of Medical Oncology, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Gizzi M; Department of Medical Oncology, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Pairet G; Department of Pathology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Lannoy V; Department of Medical Oncology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Lefesvre P; Department of Molecular Pathology, Institut de Pathologie et de Génétique (IPG), Avenue Georges Lemaître 25, 6041 Gosselies, Belgium.
Gigot JF; Department of Abdominal Surgery and Transplantation, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Hubert C; Department of Abdominal Surgery and Transplantation, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Jouret-Mourin A; Department of Pathology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Humblet Y; Department of Medical Oncology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Canon JL; Department of Medical Oncology, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Sempoux C; Department of Pathology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Chapaux X; Department of Radiolgy, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Danse E; Department of Radiology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Tinton N; Department of Abdominal Surgery, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Navez B; Department of Abdominal Surgery and Transplantation, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Van den Eynde M; Department of Medical Oncology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Nov 03; Vol. 113 (9), pp. 1298-304. Date of Electronic Publication: 2015 Oct 13.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*metabolism
Colorectal Neoplasms/*pathology
ErbB Receptors/*agonists
Neovascularization, Pathologic/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Irinotecan ; Male ; Middle Aged ; Neovascularization, Pathologic/metabolism ; Neovascularization, Pathologic/pathology ; Organoplatinum Compounds/therapeutic use ; Oxaliplatin ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Autorzy:
Stein A; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Atanackovic D; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Hildebrandt B; Charité Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, Berlin 10117, Germany.
Stübs P; University Hospital Magdeburg, Leipziger Strasse 44, Magdeburg 39120, Germany.
Brugger W; Schwarzwald-Baar Klinikum, Klinikstrasse 11, Villingen-Schwenningen 78052, Germany.
Hapke G; Marienkrankenhaus, Alfredstrasse 9, Hamburg 22087, Germany.
Steffens CC; MVZ Hämatologie/Onkologie Klinik Dr Hancken, Harsefelder Str. 8, Stade 21680, Germany.
Illerhaus G; Klinikum Stuttgart, Kriegsbergstraße 60, Stuttgart 70174, Germany.
Bluemner E; Ecron Acunova GmbH, Hahnstrasse 70, Frankfurt 60528, Germany.
Stöhlmacher J; Tumorgenetik Bonn, Maximilianstrasse 28d, Bonn 53111, Germany.
Bokemeyer C; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 15; Vol. 113 (6), pp. 872-7. Date of Electronic Publication: 2015 Sep 03.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Colorectal Neoplasms/*drug therapy
Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/mortality ; Disease-Free Survival ; Feasibility Studies ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Genes, ras ; Humans ; Induction Chemotherapy/methods ; Irinotecan ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Maintenance Chemotherapy/methods ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Oxaliplatin ; Severity of Illness Index
SCR Protocol:
FOLFOXIRI protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Autorzy:
Saridaki, Z
Androulakis, N
Vardakis, N
Vamvakas, L
Kabouraki, E
Kalbakis, K
Hatzidaki, D
Voutsina, A
Mavroudis, D
Georgoulias, V
Souglakos, J
Pokaż więcej
Źródło:
British Journal of Cancer. 12/4/2012, Vol. 107 Issue 12, p1932-1937. 6p. 4 Charts.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.
Autorzy:
Michael M; 1] Division of Cancer Medicine, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia [2] The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia.
Chander S; Division of Radiation Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
McKendrick J; Department of Medical Oncology, Box Hill Hospital, Melbourne, Victoria, Australia.
MacKay JR; Division of Surgical Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Steel M; Department of Surgery, Box Hill Hospital, Melbourne, Victoria, Australia.
Hicks R; 1] The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia [2] Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Heriot A; Division of Surgical Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Leong T; Division of Radiation Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Cooray P; Department of Medical Oncology, Box Hill Hospital, Melbourne, Victoria, Australia.
Jefford M; 1] Division of Cancer Medicine, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia [2] The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia.
Zalcberg J; Division of Cancer Medicine, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Bressel M; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
McClure B; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Ngan SY; Division of Radiation Oncology, Lower Gastrointestinal Tumour Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Nov 11; Vol. 111 (10), pp. 1924-31. Date of Electronic Publication: 2014 Sep 11.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Chemoradiotherapy*
Adenocarcinoma/*therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Liver Neoplasms/*therapy
Lung Neoplasms/*therapy
Pelvic Neoplasms/*therapy
Rectal Neoplasms/*therapy
Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Feasibility Studies ; Female ; Fluorouracil/administration & dosage ; Follow-Up Studies ; Humans ; Leucovorin/administration & dosage ; Liver Neoplasms/mortality ; Liver Neoplasms/secondary ; Lung Neoplasms/mortality ; Lung Neoplasms/secondary ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Pelvic Neoplasms/mortality ; Pelvic Neoplasms/secondary ; Prognosis ; Radiotherapy Dosage ; Rectal Neoplasms/mortality ; Rectal Neoplasms/pathology ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Autorzy:
Wang X; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zuo D; Key Laboratory of Cancer Prevention and Therapy, Department of Clinical Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Chen Y; Guangdong Provincial Key Laboratory of Gastroenterology, Department of Digestive Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Li W; Department of Cardiovascular Medicine, Tianjin Chest Hospital, Tianjin 300000, China.
Liu R; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
He Y; Department of Hepatology and Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Ren L; Key Laboratory of Cancer Prevention and Therapy, Department of Clinical Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zhou L; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Deng T; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Wang X; Guangdong Provincial Key Laboratory of Gastroenterology, Department of Digestive Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Ying G; Laboratory of Cancer Cell Biology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Ba Y; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Nov 11; Vol. 111 (10), pp. 1965-76. Date of Electronic Publication: 2014 Oct 16.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Resistance, Neoplasm*
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Colorectal Neoplasms/*metabolism
ErbB Receptors/*metabolism
Syndecan-1/*metabolism
Aged ; Apoptosis/drug effects ; Biomarkers, Tumor/metabolism ; Blotting, Western ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Case-Control Studies ; Cell Proliferation/drug effects ; Cisplatin/administration & dosage ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Female ; Flow Cytometry ; Fluorescent Antibody Technique ; Fluorouracil/administration & dosage ; Humans ; Immunoenzyme Techniques ; Irinotecan ; Male ; Matrix Metalloproteinase 7/metabolism ; Neoplasm Grading ; Neoplasm Invasiveness ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Paclitaxel/administration & dosage ; RNA, Messenger/genetics ; RNA, Small Interfering/genetics ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; Syndecan-1/antagonists & inhibitors ; Syndecan-1/genetics ; Tumor Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer.
Autorzy:
Ramcharan KS; 1] Department of Medicine, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham B18 7QH, UK [2] Department of Surgery, Russell's Hall Hospital, Dudley DY1 2HQ, UK.
Lip GY; Department of Medicine, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham B18 7QH, UK.
Stonelake PS; Department of Surgery, Russell's Hall Hospital, Dudley DY1 2HQ, UK.
Blann AD; Department of Medicine, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham B18 7QH, UK.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Oct 28; Vol. 111 (9), pp. 1742-9. Date of Electronic Publication: 2014 Sep 11.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers/*analysis
Colorectal Neoplasms/*metabolism
Endothelial Cells/*metabolism
Neovascularization, Pathologic/*diagnosis
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Bevacizumab ; Colorectal Neoplasms/blood supply ; Colorectal Neoplasms/drug therapy ; Endothelial Cells/drug effects ; Endothelial Cells/pathology ; Female ; Fluorouracil/administration & dosage ; Follow-Up Studies ; Humans ; Leucovorin/administration & dosage ; Male ; Neoplasm Staging ; Neovascularization, Pathologic/blood ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Prognosis ; Vascular Endothelial Growth Factor A/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
Autorzy:
Golan T; 1] The Oncology Institute the Chaim Sheba Medical Center, Tel Hashomer, Israel [2] The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Kanji ZS; 1] Department of Surgery, University Health Network, Toronto, ON, Canada [2] Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
Epelbaum R; 1] Department of Oncology, Rambam Health Care Campus, University of Haifa, Haifa, Israel [2] Technion, Faculty of Medicine, Haifa, Israel.
Devaud N; 1] Department of Surgery, University Health Network, Toronto, ON, Canada [2] Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
Dagan E; 1] Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel [2] Institute of Human Genetics, Rambam Health Care Campus, University of Haifa, Haifa, Israel.
Holter S; 1] Department of Surgery, University Health Network, Toronto, ON, Canada [2] Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
Aderka D; 1] The Oncology Institute the Chaim Sheba Medical Center, Tel Hashomer, Israel [2] The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Paluch-Shimon S; 1] The Oncology Institute the Chaim Sheba Medical Center, Tel Hashomer, Israel [2] The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Kaufman B; 1] The Oncology Institute the Chaim Sheba Medical Center, Tel Hashomer, Israel [2] The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Gershoni-Baruch R; 1] Technion, Faculty of Medicine, Haifa, Israel [2] Institute of Human Genetics, Rambam Health Care Campus, University of Haifa, Haifa, Israel.
Hedley D; Department of Surgery, University Health Network, Toronto, ON, Canada.
Moore MJ; Department of Surgery, University Health Network, Toronto, ON, Canada.
Friedman E; 1] The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel [2] The Susanne Levy Gertner Oncogenetics Unit Chaim Sheba Medical Center, Tel Hashomer, Israel.
Gallinger S; 1] Department of Surgery, University Health Network, Toronto, ON, Canada [2] Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Sep 09; Vol. 111 (6), pp. 1132-8. Date of Electronic Publication: 2014 Jul 29.
Typ publikacji:
Journal Article
MeSH Terms:
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
Carcinoma, Pancreatic Ductal/*genetics
Pancreatic Neoplasms/*genetics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Pancreatic Ductal/mortality ; Carcinoma, Pancreatic Ductal/pathology ; Carcinoma, Pancreatic Ductal/therapy ; Cisplatin/administration & dosage ; Disease-Free Survival ; Female ; Genetic Markers ; Humans ; Male ; Middle Aged ; Mutation ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/therapy ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Autorzy:
Hezel AF; Division of Hematology/Oncology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
Noel MS; Division of Hematology/Oncology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
Allen JN; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Abrams TA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yurgelun M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Faris JE; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Goyal L; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Clark JW; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Blaszkowsky LS; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Murphy JE; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Zheng H; Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Khorana AA; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Connolly GC; Division of Hematology/Oncology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
Hyrien O; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
Baran A; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
Herr M; Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA.
Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sheehan S; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Harris DJ; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Regan E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Borger DR; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Fuchs C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ryan DP; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Zhu AX; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Jul 29; Vol. 111 (3), pp. 430-6. Date of Electronic Publication: 2014 Jun 24.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biliary Tract Neoplasms/*drug therapy
Gallbladder Neoplasms/*drug therapy
Adenocarcinoma/mortality ; Adenocarcinoma/secondary ; Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Biliary Tract Neoplasms/mortality ; Biliary Tract Neoplasms/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Female ; Gallbladder Neoplasms/mortality ; Gallbladder Neoplasms/pathology ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Panitumumab ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins p21(ras) ; Treatment Outcome ; ras Proteins/genetics ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
Autorzy:
Feliu J; Hospital Universitario La Paz, 28046 Madrid, Spain.
Salud A; Hospital Arnau de Vilanova de Lleida, 25198 Lleida, Spain.
Safont MJ; Hospital Universitario Clinico de Valencia, 46010 Valencia, Spain.
García-Girón C; Hospital General Yagüe, 09005 Burgos, Spain.
Aparicio J; Hospital La Fe de Valencia, 46026 Valencia, Spain.
Vera R; Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
Serra O; Hospital de St Joan d'Espi Moises Broggi, 08970 Sant Joan Despi, Barcelona, Spain.
Casado E; Hospital Infanta Sofía, 28702 Madrid, Spain.
Jorge M; Complejo Hospitalario Xeral Cíes, 36204 Vigo (Pontevedra), Spain.
Escudero P; Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.
Bosch C; Hospital General de Valencia, Avenue Tres Cruces, 2, 46014 Valencia, Spain.
Bohn U; Hospital Universitario de Gran Canaria Doctor Negrin, 35010 Las Palmas de Gran Canaria, Spain.
Pérez-Carrión R; Hospital Quiron, 28223 Madrid, Spain.
Carmona A; Hospital General Universitario Morales Meseguer, 30008 Murcia, Spain.
Martínez-Marín V; Hospital Universitario La Paz, 28046 Madrid, Spain.
Maurel J; Hospital Clinico y Provincial de Barcelona, 08036 Barcelona, Spain.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Jul 15; Vol. 111 (2), pp. 241-8. Date of Electronic Publication: 2014 Jun 19.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*drug therapy
Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Bevacizumab ; Capecitabine ; Colorectal Neoplasms/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/analogs & derivatives ; Humans ; Male ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Autorzy:
Goldstein, D
Spry, N
Cummins, M M
Brown, C
van Hazel, G A
Carroll, S
Selva-Nayagam, S
Borg, M
Ackland, S P
Wratten, C
Shapiro, J
Porter, I W T
Hruby, G
Horvath, L
Bydder, S
Underhill, C
Harvey, J
Gebski, V J
Pokaż więcej
Źródło:
British Journal of Cancer. 1/3/2012, Vol. 106 Issue 1, p61-69. 9p. 1 Diagram, 5 Charts, 3 Graphs.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
Autorzy:
Kim, K.-p.
Jang, G.
Hong, Y. S.
Lim, H.-S.
Bae, K.-s.
Kim, H.-S.
Lee, S. S.
Shin, J.-G.
Lee, J.-L.
Ryu, M.-H.
Chang, H.-M.
Kang, Y.-K.
Kim, T. W.
Pokaż więcej
Źródło:
British Journal of Cancer. 2/15/2011, Vol. 104 Issue 4, p605-612. 8p. 4 Charts, 4 Graphs.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Autorzy:
Zarate, R.
Rodríguez, J.
Bandres, E.
Patiño-Garcia, A.
Ponz-Sarvise, M.
Viudez, A.
Ramirez, N.
Bitarte, N.
Chopitea, A.
Gacía-Foncillas, J.
Rodríguez, J (AUTHOR)
Patiño-Garcia, A (AUTHOR)
Gacía-Foncillas, J (AUTHOR)
Pokaż więcej
Źródło:
British Journal of Cancer. 3/15/2010, Vol. 102 Issue 6, p987-994. 8p. 4 Charts, 1 Graph.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Autorzy:
Wagner, A. D.
Buechner-Steudel, P.
Moehler, M.
Schmalenberg, H.
Behrens, R.
Fahlke, J.
Wein, A.
Behl, S.
Kuss, O.
Kleber, G.
Fleig, W. E.
Pokaż więcej
Źródło:
British Journal of Cancer. 12/7/2009, Vol. 101 Issue 11, p1846-1852. 7p. 1 Diagram, 3 Charts, 2 Graphs.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Autorzy:
Vasile, E.
Masi, G.
Fornaro, L.
Cupini, S.
Loupakis, F.
Bursi, S.
Petrini, I.
Di Donato, S.
Brunetti, I. M.
Ricci, S.
Antonuzzo, A.
Chiara, S.
Amoroso, D.
Andreuccetti, M.
Falcone, A.
Pokaż więcej
Źródło:
British Journal of Cancer. 6/2/2009, Vol. 100 Issue 11, p1720-1724. 5p. 1 Diagram, 2 Charts, 1 Graph.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
Autorzy:
Schønnemann, K. R.
Jensen, H. A.
Yilmaz, M.
Jensen, B. V.
Larsen, O.
Pfeiffer, P.
Schønnemann, K R (AUTHOR)
Jensen, B Y (AUTHOR)
Pokaż więcej
Źródło:
British Journal of Cancer. 9/16/2008, Vol. 99 Issue 6, p858-861. 4p. 2 Charts, 1 Graph.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 486

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies